Kiniksa Pharmaceuticals, a clinical-stage biotech developing treatments for autoinflammatory and autoimmune conditions, announced terms for its IPO on Monday.
The Lexington, MA-based company plans to raise $126 million by offering 7 million shares at a price range of $17 to $19. Insiders intend to purchase $50 million (40% of deal size) of the IPO. At the midpoint of the proposed range, Kiniksa Pharmaceuticals would command a fully diluted market value of $905 million.
Kiniksa Pharmaceuticals was founded in 2015 and plans to list on the Nasdaq under the symbol KNSA. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal. It is expected to price during the week of May 21, 2018.
